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2434 | Chem. Sci., 2015, 6, 2434–2443protein surface recognition using
chiral oligoamide proteomimetic foldamers†
Valeria Azzarito,ab Jennifer A. Miles,ab Julie Fisher,a Thomas A. Edwards,bc
Stuart L. Warrinerab and Andrew J. Wilson*ab
The development of foldamers capable of selective molecular recognition of solvent exposed protein
surfaces represents an outstanding challenge in supramolecular chemical biology. Here we introduce an
oligoamide foldamer with well-deﬁned conformation that bears all the hallmarks of an information rich
oligomer. Speciﬁcally, the foldamer recognizes its target protein hDM2 leading to inhibition of its
protein–protein interaction with p53 in a manner that depends upon the composition, spatial projection
and stereochemistry of functional groups appended to the scaﬀold. Most signiﬁcantly, selective inhibition
of p53/hDM2 can be achieved against four other targets and the selectivity for p53/hDM2 inhibition
versus Mcl-1/NOXA-B inhibition is critically dependent upon the stereochemistry of the helix mimetic.Introduction
The ability to understand and manipulate biological function
using molecules programmed with specic and selective
molecular recognition properties is a challenging but crucial
objective. In its ultimate embodiment, the ability to design and
synthesize molecules that eﬀectively mimic the structure and
function of protein secondary and tertiary structure1–5 using
abiotic repeat backbones would begin to answer the question:
“is the proteinogenic code for 3D structure and recognition
limited to polymers of a-amino acids?” A well-dened “code”
has been elaborated for DNA recognition that makes use of
polyamides assembled from a limited set of monomer building
blocks,6 but an equivalent code remains elusive for protein
surface recognition. There are some notable examples of
supramolecular binding motifs for protein surfaces that have
been developed to target particular residues;7,8 however, these
are not suﬃciently information rich to achieve selective recog-
nition when challenged with similar targets. Non-natural scaf-
folds are hence required that can reproduce the protein-binding
specicity and selectivity of the natural-ligands upon which they
are based9 and which are amenable to predictable sequence
based optimization.10–12 In this context we and others have been
developing inhibitors of a-helix mediated13–15 protein–protein
interactions (PPIs).16,17 Although inhibitors of helix mediatedWoodhouse Lane, Leeds, LS2 9JT, UK.
r Biology, University of Leeds, Woodhouse
, University of Leeds, Woodhouse Lane,
tion (ESI) available. See DOI:PPIs have been identied through conventional drug discovery
methods18,19 with the specic objective of advancing therapeu-
tics discovery/development, a diﬀerent approach is needed to
realize the goals of sequence based design. Two generic
approaches have been proposed: (i) by using an oligomer which
reproduces the local topography of the helical fold13 and (ii) by
employing a small molecule scaﬀold termed a “proteomimetic”20
to orient functionality in a manner that reproduces the spatial
and angular positioning of key side chains presented by the
helix donor.13 For the former, the development of conforma-
tionally constrained peptides has shown promising advantages
for functionality21 and therapeutic potential,22 whilst studies on
b-peptides have illustrated that mixed a/b-sequences10,11,23,24 or
wholly b-sequences,25 can eﬀectively inhibit PPIs. Although
such studies illustrate the requirement for correct spatial rela-
tionship of hot-spot26 side-chains, the approach relies on
reproducing the helical fold as closely as possible to achieve
recognition. In contrast, the proteomimetic approach seeks to
identify modular sequences of reduced complexity that are
orthogonal to the natural sequence in terms of topology but
compatible in terms of recognition complementarity. Proteo-
mimetics20 have been identied that are selective for their
targets in biophysical assays27–29 depending on the composition
of variable functionality added to the scaﬀold, alongside reports
illustrating targeting in cellulo30 and in vivo.31 Despite these
promising results, the fundamental parameters determining
selective recognition by proteomimetics remain poorly dened.
The purpose of this study was to determine whether the spatial
and angular projection of key side chains can interplay in
reduced complexity proteomimetic systems to provide recog-
nition motifs that exhibit the hallmarks of an information rich
system capable of programmed or coded interaction with
proteins. We do so using an oligoamide proteomimetic20This journal is © The Royal Society of Chemistry 2015
Fig. 1 (a) Schematic representing the design of a hybrid a-helix
mimetic (right) and its comparison with an O-alkylated benzamide
mimetic (left) and an a-helix (middle). (b) p53/hDM2 PPI with expan-
sion on the native p53 peptide (PDB ID:1YCR). (c) Schematic illustrating
the process of PPI inhibition with a proteomimetic. (d) Investigation of
the accessible conformational space (shown as a shaded 3D object)
highlighting the orientation of the side chains (shown in CPK format):
side (top left) and top (bottom left) view of a 3-O-alkylated trimer; side
(top right) and top (bottom right) view of a hybrid mimetic (i, i + 4 and
i + 7 side chains together with residues that mimic them are shown in
red, green and blue respectively).
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View Article Onlinescaﬀold assembled using robust solid-phase synthesis that is
capable of reproducing the vectoral presentation of side chains
projecting from the i, i + 4 and i + 7 positions of an a-helix. As a
model protein we selected hDM2 which is a well characterized32
helix binding protein. Our goal was not to add to the plethora of
optimized small molecules already identied and in clinical
development for this target. Instead, our goal was to understand
the rules that govern molecular recognition. Our biophysical
analyses, reveal that recognition of hDM2 – and therefore
inhibition of the p53/hDM2 interaction – is dependent upon the
side chain composition and spacing between monomer units
and that the selectivity of inhibition of p53/hDM2 versus Mcl-1/
NOXA-B33 can be switched by varying the stereochemistry of the
central monomer in the mimetic – an observation that illus-
trates for the rst time the importance of stereochemistry for a-
helix mimetic foldamers. This study suggests these scaﬀolds
show all the hallmarks required of an informational oligomer34
and show promise for the further construction of recognition
codes which extend beyond oligomers of a-amino acids.
Results
Design of a new hybrid a-helix mimetic and preliminary in
silico studies
A key premise upon which helix mimetics are typically designed
is that they should be based on a relatively rigid scaﬀold and
reproduce exactly the distances and angular relationship
between key side chains from the native a-helical template upon
which they are based.35 However, experimental36 and compu-
tational investigations37,38 have shown that such scaﬀolds nor-
mally adopt a range of conformations, and only some of these
are able to mimic the required pharmacophore. The design of
an eﬀective helix mimetic ought, hence, to be rened to
consider the conformational plasticity of the mimetic itself
alongside the dynamic nature of the target protein and thus the
potential for induced t between ligand and protein to occur.39
Indeed whether rigid conformational control is actually desir-
able for eﬀective mimicry remains to be established.
Building on our studies of homo-oligobenzamide a-helix
mimetics,36,40,41 we designed a new mimetic with distinct H-
bonding capabilities and stereoelectronic restraints. The back-
bone was varied by substitution of the middle aryl unit with an
a-amino acid to generate a ‘hybrid’ a-helix mimetic (Fig. 1a)
designed to mimic the i, i + 4 and i + 7 side-chains of an a-helix.
Although heterofoldamers42 containing both aromatic and
aliphatic amino acid building blocks are known,43,44 the scaﬀold
described in this work has not previously been described. As a
helix donor to mimic, we selected p53 which forms a PPI with
hDM2 as an acceptor; the Phe19, Trp23 and Leu26 of p53 are
known hot-spot residues which should be mimicked (Fig. 1b).32
This PPI represents a classic model system for therapeutics
discovery45 and test system for novel helix mimetic scaf-
folds.25,27,46–50 Appendage of functional groups that eﬀectively
mimic hot-spot residues to the scaﬀold would be expected to
result in hDM2 recognition and inhibition of the p53/hDM2 PPI
(Fig. 1c). It was envisaged that this new scaﬀold could adopt
relatively well dened conformations through intramolecularThis journal is © The Royal Society of Chemistry 2015hydrogen bonding at the top and bottom of the sequence, but
that the a-amino acid may allow access to multiple conformers
of similar energy and thus a wider range of pharmacophores.
To assess the conformational plasticity further, molecular
modelling was used to perform a qualitative comparison of a 3-
O-alkylated trimethyl benzamide and a methyl functionalised
hybrid mimetic (Fig. 1d). Methyl side chains were chosen to
exclude side chain rotations and focus only on the inherent
exibility of the backbone. The structures were minimised by
performing a full Monte Carlo search using the sowareChem. Sci., 2015, 6, 2434–2443 | 2435
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View Article OnlineMacromodel® with the MMFFs method. The set of conformers
within 1.5 kJ mol1 of the minimum were superimposed
without further manipulation. As shown in Fig. 1d, the 3-O-
alkylated oligobenzamide trimer presented diﬀerent combina-
tions of anti and syn orientations51 of the side chains but the
accessible conformational space was restricted by the rigidity of
the scaﬀold and by intramolecular hydrogen bonding such that
variation arises only through rotation about each of the Ar–CO
axes. In contrast, for the hybrid mimetic a diﬀerence of a few
degrees in a bond torsion angle can result in diverse side chain
orientations. Within the limitations of this qualitative analysis,
the study revealed that this new scaﬀold could therefore mimic
a wider range of pharmacophores, suggesting that a greater
number of conformers for eﬀective mimicry can be sampled
and the possibility for induced-t binding to occur.Synthesis of hybrid a-helix mimetics and conformational
analyses
In designing the new a-helix mimetic scaﬀold, a solid phase
synthesis (SPS) strategy was desired to allow rapid access to
large numbers of compounds/libraries. The synthesis (Scheme 1)
uses the well-established Fmoc (9-uorenylmethyloxycarbonyl)
strategy. Hybrid a-helix mimetics were built using an auto-
mated microwave assisted CEM Liberty® peptide synthesiser
with Fmoc–Gly preloaded Wang resin as solid support. Aer
resin deprotection with piperidine, protected monomers were
coupled using HATU ((1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexauorophosphate)).
The successful use of HATU as a coupling reagent is particularly
noteworthy, as standard peptide synthesis coupling reagents
have been previously shown to be ineﬀective to couple poorlyScheme 1 SPS synthesis of hybrid a-helix mimetics.
2436 | Chem. Sci., 2015, 6, 2434–2443nucleophilic aminobenzoic acid building blocks.52,53 With a
synthetic route in hand, a small library of compounds (1–17,
Fig. S2–144†) was synthesized, including parent mimetic 1
presenting R1 ¼ iPr, R3 ¼ Bn and L-Phe as the central amino
acid. Five control molecules were also prepared (Fig. 2a): three
dimeric versions of the hybrid scaﬀold (2–4), a hybrid with an
unfunctionalised p-aminobenzoic acid top unit (5, syntheses
shown in Schemes S3 and S4, ESI†) and nally a control with the
central aromatic residue replaced with histidine 6 R1¼ iPr, R2¼
L-His, R3 ¼ Bn. Histidine was chosen as a control rather than
alanine, because it is sterically comparable to phenylalanine but
is less hydrophobic.
Solution-state analyses were conducted on the model hybrid
mimetic 1 to elucidate its conformational properties. The 2D
1H–1H NOESY experiment (Fig. S145 and 146†) showed nOe
correlations between the amide protons of the top two units and
the ArCH resonances in the ortho position of the adjacent
monomer units, indicating free rotation around the Ar–CO and
NH–Ar axes. Furthermore, nOe correlations between the NH
and the Ha proton of the isopropyl side chain, together with the
absence of cross peaks to the ArCH resonances in the ortho and
meta positions of the adjacent monomer unit indicated
restricted rotation around this Ar–CO axis and intramolecular
S(6) H-bonding with the oxygen of the adjacent isopropyl
moiety. Intramolecular H-bonding was further conrmed by
dilution and variable temperature (VT) NMR studies (see ESI,
Fig. S147 and 148†). The fully assigned spectra were used to
produce a model of the minimum energy structure of helix
mimetic 1. Assigned ROESY cross-peaks were integrated using
SPARKY 3.111 (ref. 54) and volumes converted to distances with
reference to the xed and known distance between the H5 and
H6 protons of residue 4 (the N-terminal amino benzoic acid).
These distances were then used within CNS-solve55 to generate a
set of low energy structures, following a simulated annealing
process, all satisfying the distance constraints, in a similar
manner to that adopted recently for a similar sized peptide.56 Of
particular note are strong, inter-residue rOes (indicative of short
inter-proton separations) between 4-H2 and 3-Phe–NH, 4-H2
and 3-Phe–Hb. The data indicate the presence of one major
conformer (although it is noteworthy that additional nOe's
(and rOe's) were indicative of a second conformer, for which
there was insuﬃcient data to obtain a structure). The structure
obtained (Fig. 2b) illustrates the minimum energy structure –
as can be seen, all the side chains are presented on one face of
the molecule as is required for eﬀective mimicry of the helix.
Thus, the NMR data would appear to indicate that the
conformational landscape of mimetic 1 is more well-dened
than is indicated by the modelling, although the two methods
are not necessarily comparable. Furthermore, this does not
preclude the mimetic from readily adopting diﬀerent confor-
mations in the presence of a target protein. Nonetheless,
structure alignment with the p53 transactivation domain, as
shown in Fig. 3b (and also Fig. S162 and 163†), further indi-
cates the compound is capable of eﬀective a-helix mimicry
(Fig. 2c); each side chain of the mimetic can adopt an orien-
tation that overlays well with the Phe19, Trp23 and Leu26 side
chains of p53.This journal is © The Royal Society of Chemistry 2015
Fig. 2 (a) Structures of a model hybrid mimetic 1 and ﬁve control derivatives 2–6. (b) NMR derived structure of compound 1 (left and right
represent the view from opposite faces). (c) Overlay of the NMR structure of mimetic 1 and p53 transactivation domain illustrating goodmatching
of side chains between mimetic and helix together with distances between key positions (left; p53 helix, middle; mimetic 1, right; overlay). (d)
Kinetics of degradation from proteolytic studies performed on hybrid 1 (red) and WT-p53 (green) treated with no enzyme (square), trypsin
(triangle), a-chymotrypsin (sphere) and proteinase K (star) in 1 : 10 000 enzyme/substrate ratio.
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View Article OnlineWe also performed proteolysis studies on mimetic 1 to
ascertain to what extent introduction of an a-amino acid in the
middle of the hybrid sequence could render the mimetics
susceptible to enzymatic degradation. The wild type (WT) p53
helix was also used for direct comparison. a-Chymotrypsin and
proteinase K were chosen for this analysis, as these enzymes
preferentially cleave amide bonds adjacent to aromatic func-
tionalities. Trypsin was used as a control, as this protease
cleaves amide bonds adjacent to arginine or lysine residues and
therefore should not degrade either substrate. The mimetic 1
and WT-p53 were treated with each enzyme (see ESI for further
details and Fig. S149 and 150†) and degradation was followed by
analytical HPLC. The data obtained were then analysed to
extract kinetic values (ESI†). As shown in Fig. 2d, the hybrid
mimetic displayed complete resistance to all three proteases.Selective inhibition of the p53/hDM2 PPI
To test the potential of the proteomimetic scaﬀold to act as a
functional a-helix mimetic, hybrid 1 and controls 2–6 were
tested in a p53/hDM2 uorescence anisotropy (FA) competition
assay (Fig. 3a and Table 1). Hybrid 1 displayed low micromolar
inhibition of this PPI (IC50 of 11.9  0.6 mM) whereas, Nutlin-3a
– a well known and potent p53/hDM2 inhibitor,57 displayed an
IC50 of 0.53  0.02 mM in this assay (see ESI Fig. S155†). The
value compares well with a previously described 3-O-alkylated
aromatic oligomer we described previously (R1 ¼ Bn, R2¼ 2-Bn,
R3¼ iPr; IC50 of 5.1  0.4 mM).40 Although mimetic 1 was shownThis journal is © The Royal Society of Chemistry 2015to be a weaker inhibitor than Nutlin-3a, it represents an
impressive starting point for a 1st generation compound and
augurs well for further potency enhancement in future studies.
The data also demonstrated that the entirety of the sequence
was required to mimic the key ‘hot spot’ residues and therefore
achieve inhibition. In this regard, the inactivity of hybrid 2
indicated that the ‘bottom’ unit plays a signicant role in
binding. Furthermore, absence of activity for hybrids 3 and 4
proved that the ‘top’ monomer was also essential for activity
and the lack of inhibition of hybrid 5 revealed that this unit
needs to be functionalised with an interacting side chain in
order to achieve molecular recognition and retain binding
aﬃnity. Finally, substitution of the central L-phenylalanine
residue with a more hydrophilic residue (hybrid 6) – L-histidine
– abrogated inhibition demonstrating the importance of the
composition of side chains.
The binding mode of the hybrid mimetic 1 was further
investigated via 1H–15N HSQC studies. HSQC spectra were
acquired for either the 15N labelled apo form of the protein (125
mM protein 100 mM sodium phosphate buﬀer at pH 7.3, 2.5%
glycerol, 1 mMDTT, 5% DMSO, 25 C) or the protein in complex
with a 200 mM solution of hybrid 1 aer overnight incubation;
distinct shis were induced upon addition of 1. Once mapped
onto the crystal structure of p53/hDM2 (PDB ID:1YCR; Fig. 2f),32
the study showed that changes were induced that were
comparable to those observed previously for WT-p53 peptide.41
Shis of residues around the helix binding cle such as Phe55Chem. Sci., 2015, 6, 2434–2443 | 2437
Fig. 3 (a) Dose–response curves of hybrids 1 (black), 2 (purple), 3
(orange), 4 (dark cyan), 5 (magenta) and 6 (dark blue) in a FA compe-
tition assay against the p53/hDM2 PPI (errors bars correspond to three
experimental replicates). (b) Top; partial 1H–15N HSQC spectrumof the
15N-labelled 125 mM solution of hDM2 (black) overlaid with the HSQC
spectrum of hDM2 (125 mM) in complex with a 200 mM solution of 1
(red), highlighting shift changes (dark blue; large shift, light blue;
medium shift, grey; no shift, white unassigned), of pertinent residues
(600 MHz, 100 mM sodium phosphate buﬀer pH 7.3, 2.5% glycerol,
1 mM DTT, 6% DMSO, 25 C), bottom; chemical shift perturbation
mapping onto the crystal structure of p53/hDM2 (PDB ID:1YCR).
Table 1 Key IC50 values obtained from FA competition assays
Compound p53/hDM2 Mcl-1/NOXA-B
Nutlin-3 0.53  0.02 mM
1 11.9  0.6 mM >100 mM
2 No inhibition No inhibition
3 No inhibition No inhibition
4 No inhibition No inhibition
5 No inhibition No inhibition
6 No inhibition No inhibition
9 21.2  2.5 mM >100 mM
12 59.7  31.9 mM >100 mM
15 9.2  0.4 mM 27.1  1.1 mM
16 11.5  0.3 mM 24.1  1.4 mM
17 25.2  1.4 mM >100 mM
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View Article Onlineand His73 (not shown in the expansion shown in Fig. 3b), which
are located at opposite edges of the hydrophobic cle, support
the notion that the mimetic binds in the peptide binding site.
Notably, shi changes at both ends of the hDM2 cle also
supported the hypothesis that the hybrid adopts an extended
conformation. We also tested control compound 3 in the
1H–15N HSQC experiment (see ESI Fig. S164 and 165†): only2438 | Chem. Sci., 2015, 6, 2434–2443minor shis in the HSQC spectrum were observed supporting
further the notion of a direct and specic interaction of 1 with
hDM2.
We then tested the compounds against four further protein–
protein interactions using FA competition assays (see ESI†) to
ascertain the extent to which mimetic 1 acts as a selective
inhibitor. We selected these targets having developed assays on
each in prior work.40,58–60 No inhibition of Bcl-xL/BAK,61 HIF-1a/
p30062 or eIF4E/eIF4G63 (see ESI Fig. S159–161†) was observed
whilst only weak inhibition of Mcl-1/NOXA-B33 interaction
(>100 mM, Table 1) was observed (see below). Proteins of the Bcl-
2 family have a central role in the regulation of apoptosis64 and
have attracted attention as targets for molecular therapeutics.19
Since BH3-only pro apoptotic proteins of this family mediate
PPIs through three or four key residues of an a-helix placed
along one face, we envisaged that hybrid a-helix mimetics might
also bind to their antiapoptotic partner, particularly given that
p53 itself has been shown to interact with both Mcl-1 and
Bcl-xL.65 Thus the absence of strong inhibition for these targets
is particularly noteworthy.
The role of side-chain spacing
The results obtained for hybrids 1–6 suggested that the
compositional properties of these mimetics play a key role for
eﬀective recognition of the target protein. To investigate the role
of spacing between interacting side chains, we designed and
synthesised hybrids 7–14 including a combination of 2-O, 3-O
and N-alkylated monomers (Fig. 4a–c and Table 1 for key
compounds). Since the alkylation topography is diﬀerent for
each of these building blocks, spacing between side chain
residues is diﬀerent and should impact upon inhibitor potency
if this is an essential feature for inhibition of the PPI. This role
of side chain spacing has not been eﬀectively explored in
previous studies on helix mimetics.
The mimetics were divided into three families (2-O, 3-O and
an N-alkylated series, named aer the rst monomeric unit at
the bottom of the sequence), and were tested in the p53/hDM2
FA competition assay. Full competition curves for the whole
library are shown in Fig. S152–154 (ESI†) and revealed a similar
trend of activity within each family. Fig. 4d shows the results for
hybrids 1, 9 and 12, which are representative of each series.This journal is © The Royal Society of Chemistry 2015
Fig. 4 (a) Cartoon depicting the design of a library of hybrid mimetics
for sequence-dependent SAR studies. (b) 2-O (green), 3-O (red) and
N-alkylated (blue) aminobenzoic acid building blocks; (c) cartoon
representation of the library of hybrid mimetics for sequence-
dependent SAR studies; (d) dose–response curves of hybrids 1 (black),
9 (magenta) and 12 (violet) in a FA competition assay against the p53/
hDM2 PPI.
This journal is © The Royal Society of Chemistry 2015
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View Article OnlineMimetics containing a 2-O alkylated building block at the
bottom position (6.98 A˚ between O and a position) displayed
better inhibitory activity than the corresponding 3-O-alkylated
hybrids (4.50 A˚ between O and a position, see Fig. S178†) and
ve fold increased potency than hybrids of the N-alkylated
series (3.10 A˚ between N and a position, see Fig. S178†). The
result demonstrates that the side chain spacing has a signi-
cant eﬀect on the binding aﬃnity, as a preferential sequence
was identied. Thus, mimetic 1 with the largest distance
between the R1 and R2 side chains (mimicking the i + 7 and i + 4
positions of the helix) is optimal for recognition of hDM2 and
inhibition of the p53/hDM2 interaction in this instance. The
result is signicant; despite having a diﬀerent degree of back-
bone curvature, the previously reported regioisomeric 2-O and
3-O-alkylated oligobenzamide mimetics were shown to have
comparable potency for inhibition of the p53/hDM2 interac-
tion36 because free rotation of multiple bonds within a
repeating structure permit similar vectoral presentation of hot-
spot mimicking residues. Here, for the hybrid mimetic 1 –
which might be thought of as more exible due to greater
variation in the accessible conformational space of the scaﬀold
– the irregular backbone allows the spatial relationship to be
varied for only two of the three residues in the mimetic at a time
and so the distance between these residues must diﬀer. As the
hDM2 cle is hydrophobic in nature, the preliminary Structure
Activity Relationship (SAR) data for 1–6 might simply reect an
increase in non-specic hydrophobic interactions, however the
fact that inhibitory potency varies for the series 1, 9 and 12
critically illustrates that in addition to the compositional
complementarity of the helix mimetic and protein-surface,
there must also be some shape complementarity. Finally, the
series 1 and 7–14 was also tested in the Mcl-1/NOXA-B compe-
tition assay. All these mimetics showed little inhibitory activity
against this PPI (Table 1 and full competition curves shown in
Fig. S156–158†) indicating a good level of selectivity towards
recognition of the hDM2 cle is retained.Stereodependent inhibitory behaviour of a-helix mimetics
Whilst several helix mimetics incorporate stereogenic centres in
the backbone or chiral appendages,29,48,50,66–70 a role for stereo-
chemistry in molecular recognition has not been demonstrated.
The use of an a-amino acid as the central monomer of the
mimetic allows access to enantiomeric helix mimetics and thus
permits the role of stereochemistry on inhibitory activity to be
probed. The chirality of many small molecules is pivotal for
eﬀective binding to their target and represents a hallmark of
specic and selective molecular recognition. We therefore syn-
thesised the enantiomer of 1 i.e. 15 with a D-Phe residue
(Fig. 5a). Disappointingly, there was little diﬀerence in the
inhibitory potencies of 1 and 15 against the p53/hDM2 inter-
action (Fig. 5b and Table 1). In our preliminary selectivity
studies (above) we had observed weak inhibition of the Mcl-1/
NOXA-B interaction with compound 1, however the compound
was not suﬃciently potent to obtain a full competition curve in
this assay. We therefore attempted to conrm that the role of
stereochemistry was not important in this series of helixChem. Sci., 2015, 6, 2434–2443 | 2439
Fig. 5 (a) Chemical structure of the D-Phe functionalised hybrid mimetic 15. (b) Dose–response curves of L-Phe (1) and D-Phe (15) hybrid
mimetics in FA competition assays against p53/hDM2 (left) and Mcl-1/NOXA-B (right). (c) Docking and 1H–15N HSQC perturbation shift studies
(dark blue; large shift/peak disappears, light blue; medium shift, grey; no shift, white unassigned) with hDM2 (PDB ID:1YCR): docked hybrid 1with
protein surface 3D representation and chemical shift mapping (left), docked hybrid 15 with protein surface 3D representation and chemical shift
mapping (right). (d) Docking and 1H–15N HSQC perturbation shift studies with Mcl-1 (PDB ID:2JM6): docked hybrid 1 with protein surface 3D
representation and chemical shift mapping (left), docked hybrid 15 with protein surface 3D representation and chemical shift mapping (right).
Spectra recorded at 600 MHz, in 20 mM HEPES pH 7.0, 50 mM NaCl, 0.5 mM DTT, 2.5% glycerol, 5% DMSO at 25 C.
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View Article Onlinemimetics by studying the inhibition of the Mcl-1/NOXA-B
interaction with 15. Signicantly, 15 was observed to act as an
inhibitor of the Mcl-1/NOXA-B interaction being around one
order of magnitude more potent than the L-Phe variant 1
(Fig. 5b and Table 1). It is also noteworthy that the Mcl-1/NOXA-
B interaction involves a signicantly longer helix than does p53/
hDM2 (20 versus 9 residues) hence the result with 15 demon-
strates that the scaﬀold may be useful for recognition of longer
helix binding cles. We performed 1H–15N HSQC perturbation
shi studies to investigate this behaviour. The HSQC of the
complex 15/hDM2 (see ESI, Fig. S166 and 167†) was consistent
with the perturbation shis obtained with hybrid 1. Shown in
Fig. 5c is the hDM2 structure with shis mapped onto the
surface – as can be seen these are similar in nature for both 1
and 15 emphasising the absence of any diﬀerence in inhibitory2440 | Chem. Sci., 2015, 6, 2434–2443potency. 1H–15N HSQC analyses of both hybrids in complex with
Mcl-1 (see Fig. S168–171†), indicated diﬀerent behaviour for 1
and 15 (Fig. 5d). For compound 15, a signicantly higher
number of resonances exhibit a larger shi or disappear
completely from the 1H–15N HSQC spectrum of Mcl-1 than for
compound 1. This disappearance of resonances is signicant as
it indicates slower exchange and therefore higher aﬃnity
binding. Again, we observed only minor shis in the 1H–15N
HSQC spectrum upon addition of the non-binding control
compound 3 (Fig. S172 and 173†).
To provide a molecular hypothesis for this behaviour, we
also performed docking studies. The structures of hybrids 1 and
15 were minimised by performing a full Monte Carlo search
using the soware Macromodel® with the MMFFs method. The
set of structures within 1.5 kJ mol1 from the lowest energyThis journal is © The Royal Society of Chemistry 2015
Fig. 6 (a) Chemical structure of the Trp-functionalised hybrid
mimetics 16 and 17. (b) Dose–response curves of hybrid mimetics in
FA competition assays against p53/hDM2 (top) and Mcl-1/NOXA-B
(bottom).
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View Article Onlineconformation was initially docked with the crystal structure of
hDM2 (PDB ID:1YCR) using the soware Glide®. Of all the
poses generated from hybrids 1 and 15, 77% and 69% respec-
tively assumed conformations which were binding in the hDM2
cle. Representative examples are shown in Fig. 5c. The docking
results indicate that the mimetics are indeed capable of acting
as structural mimics of the a-helix and suggest why there is no
discrimination between the enantiomers 1 and 15, employing L-
Phe and D-Phe respectively; clearly both are capable of adopting
conformations where the top residue and the amino acid can
occupy the Phe19 and Trp23 pockets respectively. Docking
experiments were also performed with the crystal structure of
Mcl-1 (PDB ID:2JM6). Only 3% of the poses generated from L-
hybrid 1 assumed conformations which were binding in the
Mcl-1 cle. Most of the structures instead adopt conformations
where the backbone of the two bottom residues binds to the
cle thus inducing the side chains to engage in interactions
with amino acids outside the NOXA-B binding pocket. A
representative example is shown in Fig. 5d. Within the
constraints of the method (limitations of the force elds,
assumptions regarding conformational restrictions and media
for simulation), this analysis indicates that the side chains of
this hybrid are not matched to the NOXA-B sequence and that
this molecule does not act as a good mimetic of the NOXA-B
helix. On the other hand, of the poses generated from hybrid 15,
62% assumed conformations binding into the Mcl-1 cle
(Fig. 5d). The D-hybrid mimetic binds in the Mcl-1 cle with all
three residues through hydrophobic contacts (between the
benzyl side chain and Phe251, between the middle Phe residue
and Phe209/Ala208 and between the isopropyl side chain and
Val246). These interactions suggest good matching between the
position of the side chains of this mimetic to the NOXA-B
sequence representing a possible explanation for the enantio-
selective recognition of the mimetic 15 over 1 by the Mcl-1
protein. Why Mcl-1 discriminates between 1 and 15 more
eﬀectively than does hDM2 is unclear at this stage, however the
helix binding cles diﬀer in terms of shape and composition –
how the mimetic is able to exploit its conformational landscape
to target the respective proteins will be the focus of future
studies.
The role of stereochemistry was further highlighted using
hybrids 16 and 17, which presented a tryptophan in lieu of the
phenylalanine to mimic the natural ‘hot-spot’ residue of p53
(Fig. 6a). These compounds were synthesized in the expectation
that incorporation of the native helix side chain within the
hybrid mimetic might enhance binding to hDM2, however this
was not observed, perhaps indicating that the scaﬀold is not yet
optimal for perfect helix mimicry and that it needs further
renement in future studies. The biophysical analyses with
both hDM2 and Mcl-1 however, reveal additional binding
properties that depend onmimetic chirality. Firstly, as for 1 and
15, the protein selectivity is inuenced by mimetics stereo-
chemistry (Fig. 6b); for 17 the preference for hDM2 over Mcl-1 is
four-fold; where for the Phe derivatives 1 and 15 the D-derivative
bound to Mcl-1, for Trp derivatives 16 and 17 the opposite trend
i.e. L-Trp residue is preferred. The reason for a diﬀerence in
enantiopreference is unclear at this stage. Another pivotalThis journal is © The Royal Society of Chemistry 2015feature, not as clearly observed for the Phe series, was shown by
this series as each of the proteins exhibit a preference for one of
the enantiomers. In this instance, hDM2 displays a 2 fold
preference for the L-Trp hybrid 16 over 17, whereas for Mcl-1 the
preferences is at least four-fold. Once again docking studies
supported the experimental trend for inhibition (see Fig. S174–
177†).
Conclusions
We have described the design, synthesis and characterization of
a new oligoamide proteomimetic scaﬀold. In order for the
scaﬀold to act as a ligand for protein surface recognition, we
illustrate that the side-chains mimicking the a-helical template
upon which they are based must be positioned appropriately to
eﬀectively reproduce the spatial and angular projection of the i,
i + 4 and i + 7 side-chains of a canonical a-helix and presentChem. Sci., 2015, 6, 2434–2443 | 2441
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View Article Onlineappropriate composition to recapitulate these hot-spot resi-
dues. The stereochemistry of the central monomer of our
hybrids was found to play a signicant role in the inhibition of
target PPIs. In particular, as would be required for an infor-
mation rich oligomer exhibiting dened molecular recognition,
both hDM2 and Mcl-1 diﬀerentiate between enantiomers of the
same helix mimetic. Finally, the initial mimetic 1 was observed
to be a selective inhibitor of the p53/hDM2 interaction when
compared with 4 other PPIs. However, we were able to show that
its protein selectivity could be modulated simply by varying the
central chiral unit in the mimetic, thus leading to stereo-
dependent selectivity or dual inhibition of p53/hDM2 and Mcl-
1/NOXA-B. A denitive explanation for the diﬀerence in ster-
eodependent recognition and protein selectivity requires
further study and, similarly, the binding aﬃnity of the mimetic
might be further optimised in future work. However, the
primary goal of the current study, was to demonstrate that,
when appropriately functionalized, the scaﬀold developed
herein exhibits all the hallmarks expected of an information
rich oligomer and therefore is well-suited for future sequence
based design. Specically, the combination of stereodependent
recognition behaviour, married with correct side chain spacing
as observed in this work is unprecedented for helix mimetics. Of
consequence for future studies is the observation that this can
be achieved using a scaﬀold that has considerable exibility in
terms of its conformational properties, which contrasts with the
expectation that a helix mimetic should employ a rigid scaﬀold.
As our results clearly illustrate, the scope for induced t binding
and conformational selection should also be accounted for.
Finally, this new scaﬀold represents the most simple helix
mimetic described to date in terms of its synthesis (achieved by
SPS) and functional group tolerance, and hence will allow
access to large libraries of helix mimetics48,71,72 facilitating high-
throughput studies of protein-surface recognition.
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